Top Markets
Coin of the day
Diagnocure, Inc. Diagnocure, Inc.

Diagnocure, Inc.

DGCRF
株式のランク #41419
Diagnocure, Inc. is a Canadian life sciences company dedicated to developing... Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions. The company's portfolio includes the PCA3 test for prostate cancer diagnosis, as well as the Guanylyl Cyclase C (GCC) marker and the Previstage GCC colorectal cancer staging test, both vital for patients with colorectal cancer. They also offer PCP, a multi-marker diagnostic for prostate cancer. In addition to these tests, Diagnocure provides specialized services such as gene expression and copy number variation analysis, mutation detection, SNP genotyping, and comprehensive platform and laboratory environmental support. Established in 1994 as 9342-8530 Québec Inc. and previously known as DiagnoCure Inc., the company is headquartered in Quebec, Canada.
株価
$0.0001
最終同期: 2025-06-11
時価総額
$21.52K
変化(1日)
0.00%
変化(1年)
0.00%
CA
取引 Diagnocure, Inc. (DGCRF)

カテゴリー

Diagnocure, Inc.(DGCRF)の収益
Aug 2026 時点の収益 TTM: 0
Diagnocure, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Diagnocure, Inc. の収益履歴(2026 ~ 2026)
各年末の収益
収益 変化
提供された日付のデータは十分ではありません。